{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-089676","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.973212+00:00","generated_at":"2026-06-24T00:19:29.443417+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Leap Therapeutics reports Q2 net loss $17M, cash $90.9M; director Bertagnolli resigns for NCI role","bullets":["Net loss $17.0M in Q2 2022 ($9.5M in Q2 2021); R&D expenses $14.0M vs $7.2M, driven by manufacturing and trial costs.","Cash and equivalents $90.9M at June 30, 2022, providing expected runway into mid-2024.","Initiated Part C of DisTinGuish study (DKN-01 + tislelizumab + chemo) in first-line G/GEJ cancer; also started DeFiance study in second-line CRC.","Director Dr. Monica Bertagnolli resigned effective Aug 12, 2022 to become Director of the National Cancer Institute; no disagreement with company.","Presented initial prostate cancer data at ASCO 2022: in combination cohort, all 6 patients had >50% PSA reduction, 5 with measurable disease had partial response."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-089676","json":"https://secwatch.observer/filing/0001104659-22-089676.json","markdown":"https://secwatch.observer/filing/0001104659-22-089676.md","text":"https://secwatch.observer/filing/0001104659-22-089676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/0001104659-22-089676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/tm2223284d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:19:29.443417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63d1ea0d0a","claim":"Monica Bertagnolli resigned as director at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"On August 11, 2022, Dr. Monica Bertagnolli, a director of the Company, informed the Company that she will be resigning as a director, effective August 12, 2022, as a result of her appointment as the 16th Director of the National Cancer Institute (NCI) by the Biden administration.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/0001104659-22-089676-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}